Uri Danon, MBA - Chief Executive Officer

Mr. Danon has been our CEO since November 2009. He brings to this position operational, business and management experience in pharmaceuticals and biotechnology, having previously managed major international projects for Teva Pharmaceutical Industries Ltd., including the development of Copaxone in a solution in pre-filled syringes (a drug with sales of over $2 billion per year). He was CEO of Epigenesis (a cell therapy development company) and most recently served as CEO of Atox Bio, which develops therapeutics for autoimmune diseases and sepsis, as well as having previously been President at BioCancell.
He holds an MBA in Marketing from Bar-Ilan University, and a B.Sc. in Industrial Engineering and Management from Tel Aviv University.

Prof. Avraham Hochberg, Ph.D. (Co-Founder) - Chief Scientist

Prof. Hochberg has been our Chief Scientist since our inception. A biochemist and molecular biologist in the Department of Biological Chemistry at the Hebrew University of Jerusalem, Prof. Hochberg is recognized as a world-leading expert on the H19 gene, which plays a significant role in the tumor development process by enabling tumor cells to survive under stress conditions. He led the 19-year ground-breaking research that led to the development of BC-819. Prof. Hochberg's list of around 140 publications covers seminal contributions in the fields of imprinted genes, the H19 gene, the IGF2 gene and oncology. He holds a Ph.D. in the natural sciences, and a B.Sc. in Archeology.

Jonathan Burgin, MBA, CPA - Chief Financial Officer

Mr. Burgin has been our CFO since June 2011. From 2006 to 2011, he was CFO of Radcom, Ltd. (NASDAQ: RDCM), a service assurance provider, and was CFO of XTL Biopharmaceuticals (TASE: XTL, Pink Sheets: XTLBY), a drug development company, from 1999 to 2006, where he took an active part in the process of listing its shares on the NASDAQ, London Stock Exchange and TASE, and in raising $113 million in four financing rounds. Between 1997 and 1999, he was CFO of YLR Capital Markets, a publicly-traded Israeli investment bank, and rose to become a Senior Manager at Kesselman & Kesselman, the Israeli member of PricewaterhouseCoopers International, Ltd, between 1984 and 1997. Mr. Burgin earned an M.B.A. and a B.A. in Accounting and Economics from Tel-Aviv University and is certified in Israel as a CPA.

Monique Ben-Am, M.Sc. Vice-President, Clinical Development

Ms. Ben-Am has been our VP Clinical Development since June 2011, bringing with her over 25 years of experience in the pharmaceutical industry. Prior to joining BioCancell, she was Director of Global Operations Management & Resources, Global Clinical Operation, Global Innovative R&D at Teva Phamaceuticals, Ltd. (NASDAQ: TEVA, TASE: TEVA), where she managed an international group of Global Operations Managers responsible for multiple sclerosis, ALS, Parkinson's Disease, Crohn's Disease and oncology clinical trials. Previously, she was VP Clinical Affairs at TopSpin Medical Ltd., after many years with Novartis Pharma AG in Switzerland and the U.S. in a variety of positions. While working at Novartis' Oncology Business Unit, she managed and completed a number of clinical trials leading to the approval of the oncology blockbuster drug Glivec, the Glivec Expanded Access Program including over 7000 patients in 37 countries, and the Glivec International Patient Access Program (GIPAP) providing access to thousands of patients in the developing world. She holds a B.Sc. in Agriculture from the Hebrew University of Jerusalem, Israel, and an M.Sc. in Physiology and Pharmacology from the Tel Aviv University.

Patricia Ohana, Ph.D., Vice-President, Research & Development

Dr. Ohana has been our VP Research & Development since June 2011, and was previously our VP Clinical Development from September 2006. She is a biochemist and molecular biologist at the Hebrew University of Jerusalem where she holds a position as research scientist in the Department of Biological Chemistry. Dr. Ohana has been involved in many aspects of the ground-breaking research on the H19 gene led by Professor Hochberg. She holds a Ph.D. and M.Sc. in Biological Chemistry and a B.Sc. in Chemistry, all from the Hebrew University of Jerusalem.

Doron Amit, Ph.D., MBA, Vice-President, Business Development

Dr. Amit has been our VP Business Development since May 2010, and was previously our IP Director. He oversees BioCancell's business development activity, and is in charge of the research and development of BC-821, BioCancell's 2nd generation drug candidate, since co-inventing it together with Prof. Avraham Hochberg.
He is a former director of the US Funds Department and chief life science analyst at FreeMind Group LLC, an international consultancy firm, where he managed a team of bio-med consultants and was responsible for raising funds from non-dilutive sources such as government agencies and private foundations for biotechnology companies and research institutions. He has provided business consultancy services for various biotechnology and medical device companies in Israel and in the U.S.
Dr. Amit holds a Ph.D. in Molecular Biology and an MBA, magna cum laude, both from the Hebrew University of Jerusalem. He also holds an M.Sc., summa cum laude, in Molecular Biology, and a Bachelor of Medical Sciences, both from the Hebrew University of Jerusalem.